



ISSUE
08
Summer 2023

eyenovian

A Quarterly Update Newsletter from Eyenovia, Inc.

- CEO Welcome Message
- Eyenovia on the Russel Index
- Eyenovia Announces FDA Approval
- HR Update
- ASCRS and Octane Showcase
- All-company Disneyland Event
- Crossword Puzzle
- EyeXL Award Winners

EYENOVIA ON THE RUSSEL INDEX

Eyenovia has made it to the Russell 2000® and Russell 3000® indexes, making it possible for us to catch the attention of investors far and wide. This is a significant milestone for our small startup, propelling us towards greater visibility and growth. Get ready, because Eyenovia is poised to soar to new heights.

WELCOME TO OUR SUMMER QUARTERLY UPDATE

It's summer and the heat is on!

The Eyenovians have successfully developed the first ophthalmic spray for mydriasis and obtained FDA approval! An incredible feat when you consider how we had to complete clinical, device and electronic validation studies.

But there is not time yet to cool down. Because now we have to show that we can manufacture and sell MydCombi™. At times it can seem overwhelming, which is why it's important that we also take care of ourselves and each other. Use that PTO. Enjoy a long weekend or three. It's summer time!

Michael M. Rowe | Chief Executive Officer

EYENOVIA ANNOUNCES FDA APPROVAL OF MYDCOMBI™, THE FIRST OPHTHALMIC SPRAY FOR MYDRIASIS, WHICH ALSO LEVERAGES THE COMPANY'S PROPRIETARY OPTEJET® DEVICE PLATFORM

“The approval of MydCombi, our first FDA approved product, represents the culmination of years of tireless effort by the entire Eyenovia team, and I would like to express my sincere gratitude to the associates and technical experts who helped advance this important program through this transformational milestone,” stated Michael Rowe, chief executive officer of Eyenovia.

“Perhaps more importantly, FDA approval of MydCombi provides critical validation of the Optejet as it is the first product approved using the Optejet platform, which is core not only to our internal development programs, including MicroLine for presbyopia, but our partnered programs as well. We see opportunities to unlock significant opportunities in the future treatment of other ophthalmic conditions including glaucoma and dry eye. I am confident in our ability to maintain our current momentum.”



HR UPDATE

PTO boost for 5+ year Eyenovians

Employees who have been at Eyenovia for 5 consecutive years will begin to earn an additional week (40 hours) of Paid Time Off (PTO) accrual.

5+ year employees will accrue at the rate of 200 hours per year, and you can keep in your account up to 200 hours per year.

At the beginning of an employee's 6th year, additional PTO will begin accruing.

This policy becomes effective September 1st, 2023 for the company. No changes in how PTO can be utilized.

Leadership hopes their gratitude to employees is properly expressed via this PTO program and that PTO continues to provide a proper work-life balance for all Eyenovians.

EYENOVIA SHOWCASES AT ASCRS AND OCTANE

FDA Approval announced at ASCRS! The commercial team is excited to build out the launch of MydCombi, now FDA-approved. The first sale is expected to take place later this year, marking the first sale in our company's history!



Eyenovia was proud to be a sponsor of the **2023 Octane OTF** meeting where our very own Norbert Lowe gave a presentation on Innovations of the Future and where our Optejet® technology was the star of the show.





EYENOVIANs CELEBRATE OUR FIRST FDA APPROVAL AT DISNEYLAND

Eyenovians celebrated our first FDA approval with a fun-filled day at Disneyland! It was a day of team building while enjoying the rides and festivities of the happiest place on earth. A big THANK YOU to Shelley Malkemus for organizing this epic day.


HOW WELL DO YOU KNOW EYENOVIA? FIND OUT WITH OUR CROSSWORD

Across

2. Longest tenured Eyenovia employee
3. City where the commercial team works
4. Disease state in our pipeline that was licensed to Bausch+Lomb
9. Location of Eyenovia's second largest campus
10. Eyenovia's platform technology
11. Month of our FDA product approval
12. The name of this quarterly newsletter

Down

1. Indication Eyenovia hopes to treat using pilocarpine in the Optejet
5. State where the finance team works
6. This biggest little city is home to many Eyenovians
7. What breakfast the CEO brings to every office he visits
8. The name of our first approved product



ACROSS: 2 Peter Lam < 3 Laguna Hills < 4 Myopia < 9 Redwood City < 10 Optejet < 11 May < 12 Eyenovian
DOWN: 1 Presbyopia < 5 New York < 6 Reno < 7 Donuts < 8 MydCombi



The **eyeXL** program provides special and tangible recognition to Eyenovia employees for exceptional contributions that exceed normal responsibilities. **Nominations are accepted anytime** during the year through the Helloteam suggestion box.



KARENA EVANS

QA TEAM LEAD
QUALITY AND REGULATORY AFFAIRS

Her contribution during the FDA inspection was critical to why the facility presented so well. She worked late to ensure urgent DCOs were processed so Eyenovia could achieve a rapid response to FDA requests.

Nominated by Lauren Gidden



SHELLEY MALKEMUS

SENIOR EXECUTIVE ADMINISTRATIVE ASSISTANT
GENERAL & ADMINISTRATIVE

Shelley has improved the flow and efficiency of the Laguna Hills office. She orchestrated a fantastic all-company Disneyland Trip. Shelley is an incredibly kind person who epitomizes what it means to be an Eyenovian.

Nominated by Laguna Hills Office



JULIE WHITCOMB

SENIOR DIRECTOR OF MEDICAL AFFAIRS
CLINICAL OPERATIONS AND MEDICAL AFFAIRS

From educating KOLs about the benefits of the Optejet® platform to providing insightful suggestions for the clinical team, Julie is a key driver in the submission of several medical scientific manuscripts.

Nominated by Louis Katayama and Peter Lam



LILIAN OFULUE-EZE

HEAD OF QUALITY, REDWOOD CITY
QUALITY AND REGULATORY AFFAIRS

Lilian helped to prepare the RWC facility for the FDA audit which we successfully passed and led the effort in the pre-FDA inspection audit. She has also taken the lead in getting our RWC pharmacy license.

Nominated by Bren Kern




ERIC PIEPMEIER

MANUFACTURING ENGINEER
MANUFACTURING OPERATIONS

He worked tirelessly to install and ensure all the new equipment is up and running in Reno. Eric has dealt with several unexpected challenges quickly and to full resolution in addition to ensuring a safe working environment.

Nominated by Enrico Brambilla, Kris Rodgers, Peter Lam



MARIA OWENS

DIRECTOR OF HR AND PAYROLL
ACCOUNTING AND FINANCE

Mariia has supported the entire company in attracting, sourcing and obtaining new talent. Mariia has also helped manage- out IT, promote positive culture, schedule reviews and other HR activities.

Nominated by Bren Kern



MATTHEW FINCH

SENIOR MANAGER, PROJECT MANAGEMENT
MANUFACTURING OPERATIONS

For taking on project management responsibilities and helping to ensure that we all know where everything is to ensure timelines are met.

Nominated by Michael Rowe



MARILYN CLEMENTS-DAY

ASSEMBLER II
MANUFACTURING OPERATIONS

Marilyn traveled to Paragon to support the commercial build of Cartridge Subassemblies - without Marilyn, this build would have been infinitely more difficult.

Nominated by Bren Kern

MEET THE NEW EYENOVIANs! Enrico Brambilla – VP | Product Research & Development // Vanessa Urgel – Assembler 1
Andrea Le – Senior Director | Pharmacovigilance and Safety // Jorge Ruano – Production Manager, Redwood City
Leo Villanueva – Assembler 1 // Mark Zechmeister – Senior Electro-Mechanical Engineer



Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY, 10017
eyenovian.com

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovian.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
VP Commercial Operations
nlowe@eyenovian.com